Turbo-Charged Vaccines for Animal Health™


Man’s Best Friends Therapeutics (MBFT) is a clinical stage animal health company that is developing innovative gene-based check point inhibitor and immune-modulators for cancer and infectious diseases for use in veterinary medicine, using both viral and non-viral proprietary delivery systems. This is a technology platform from which multiple prophylactic and therapeutic vaccines can be developed for markets valued at over $5BM in the USA. Our lead product is MBFT-201 for canine melanoma. We have completed 2 pilot studies that have demonstrated the safety of our immunotherapeutic vaccine and have elicited a strong cytotoxic T-cell responses to the key antigens in 100% of the dogs treated.


In addition we have 3 infectious disease products in development. Our infectious disease products will utilize our proprietary non-viral delivery system that elicits both a T and B-cell response, is dose sparing, allows for re-administration and can be customized to optimize the immune response for each vaccine.

The Lastest in the News:

  • LinkedIn Classic
  • Facebook Classic
  • Twitter Social Icon

​Follow us at @mbftherapeutics

© 2020 MBF Therapeutics.   Advanced Immunotherapeutics for Life Sciences.  All rights reserved.